Athena Athena

X
[{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$190.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"Blacksmith Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blacksmith Medicines Announces Merger with Forge Therapeutics to Create Leading Company Developing Medicines Targeting Metalloenzymes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

Find Clinical Drug Pipeline Developments & Deals by Forge Therapeutics, Inc

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The Blacksmith metalloenzyme platform, a focused library of metal-binding pharmacophores with proprietary computational modeling, approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzyme's active site.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Recipient: Blacksmith Medicines

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger January 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under this agreement, Roche has an exclusive option to license one of Forge’s antibiotic programmes. Forge will retain control of the programme prior to Roche exercising its option.

            Lead Product(s): Antibiotics

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: $190.5 million Upfront Cash: Undisclosed

            Deal Type: Collaboration March 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY